Review article: Depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 8, 2014, Pages 880-892

  Mullish, B H ^a   Kabir, M S ^a   Thursz, M R ^a   Dhar, A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IPRONIAZID; MIRTAZAPINE; PAROXETINE; REBOXETINE; SERTRALINE; VENLAFAXINE; NEUROTRANSMITTER UPTAKE INHIBITOR;

ADVERSE OUTCOME; ALCOHOL LIVER DISEASE; AUTOIMMUNE LIVER DISEASE; CHOLESTASIS; CHRONIC LIVER DISEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HEALTH IMPACT ASSESSMENT; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MORTALITY; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PREVALENCE; REVIEW; LIVER DISEASES; PSYCHOLOGY;

ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; NEUROTRANSMITTER UPTAKE INHIBITORS;

EID: 84907903756     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12925     Document Type: Review

References (107)

1. Vos T, Flaxman AD, Naghavi M, et al,. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systemic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-96.
2. Härter M, Baumeister H, Reuter K, et al,. Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases. Psychother Psychosom 2007; 76: 354-60.
3. Baumeister H, Hutter N, Bengel J, Härter M,. Quality of life in medically ill persons with comorbid mental disorders: a systematic review and meta-analysis. Psychother Psychosom 2011; 80: 275-86.
4. Diez-Quevdeo C, Lupõn J, González B, et al,. Depression, antidepressants, and long-term mortality in heart failure. Int J Cardiol 2013; 67: 1217-25.
5. Richter P, Werner J, Heerlein A, Kraus A, Sauer H,. On the validity of the Beck Depression Inventory. A review. Psychopathology 1998; 31: 160-8.
6. Häuser W, Holtmann G, Grandt D,. Determinants of health-related quality of life in patients with chronic liver diseases. Clin Gastroenterol Hepatol 2004; 2: 157-63.
7. Bianchi G, Marchesini G, Nicolino F, et al,. Psychological status and depression in patients with liver cirrhosis. Dig Liver Dis 2005; 37: 593-600.
8. Nardelli S, Pentassuglio I, Pasquale C, et al,. Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. Metab Brain Dis 2013; 28: 239-43.
9. Singh N, Gayowski T, Wagener MM, Marino IR,. Depression in patients with cirrhosis. Impact on outcome. Dig Dis Sci 1997; 42: 1421-7.
10. Rogal SS, Landsittel D, Surman D, Chung RT, Rutherford A,. Pre-transplant depression, antidepressant use and outcomes of orthotopic liver transplantation. Liver Transpl 2011; 17: 251-60.
11. Dobbels F, Vanhaecke J, Dupont L, et al,. Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation 2009; 87: 1497-504.
12. Corruble E, Barry C, Varescon I, et al,. Report of depressive symptoms on waiting list and mortality after liver and kidney transplantation: a prospective cohort study. BMC Psychiatry 2011; 11: 182-92.
13. Iwasa M, Matsumura K, Nakagawa Y, et al,. Evaluation of cingulate gyrus blood flow in patients with liver cirrhosis. Metab Brain Dis 2005; 20: 7-17.
14. Nakagawa Y, Matsumura K, Iwasa M, et al,. Single photon emission computed tomography and statistical parametric mapping analysis in cirrhotic patients with and without minimal hepatic encephalopathy. Ann Nucl Med 2004; 18: 123-9.
15. Scheuerecker J, Meisenzahl EM, Koutsouleris N, et al,. Orbitofrontal volume reductions during emotion recognition in patients with major depression. J Psychiatry Neurosci 2010; 35: 311-20.
16. Weissenborn K, Ennen JC, Schomerus H, Rückert N, Hecker H,. Neuropsychological characterization of hepatic encephalopathy. J Hepatol 2001; 34: 768-73.
17. Barron AJ, Zaman N, Cole GD, et al,. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol 2013; 168: 3572-9.
18. DiMatteo MR, Lepper HS, Croghan TW,. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101-7.
19. Irwin M, Daniels M, Bloom ET, Smith TL, Weiner H,. Life events, depressive symptoms, and immune function. Am J Psychiatry 1987; 144: 437-41.
20. Koff WC, Fann AV, Dunegan MA, Lachman LB,. Catecholamine-induced suppression of interleukin-1 production. Lymphokine Res 1986; 5: 239-47.
21. Forton DM, Allsop JM, Main J, et al,. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358: 38-9.
22. Forton DM, Thomas HC, Murphy CA, et al,. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433-9.
23. Carta MG, Hardoy MC, Garofalo A, et al,. Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy. Clin Pract Epidemiol Public Health 2007; 3: 22.
24. el-Serag HB, Kunik M, Richardson P, Rabeneck L,. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123: 476-82.
25. Dwight MM, Kowdley KV, Russo JE, et al,. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000; 49: 311-7.
26. Golden J, O'Dwyer AM, Conroy RM,. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005; 27: 431-8.
27. Schaefer M, Capuron L, Friebe A, et al,. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012; 57: 1379-90.
28. Lee K, Otgonsuren M, Younoszai Z, Mir HM, Younossi ZM,. Association of chronic liver disease with depression: a population-based study. Psychosomatics 2013; 54: 52-9.
29. Schäfer A, Scheurlen M, Felten M, Kraus MR,. Physician-patient relationship and disclosure behaviour in chronic hepatitis C in a group of German outpatients. Eur J Gastroenterol Hepatol 2005; 17: 1387-94.
30. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kent KC,. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepatitis 2007; 14: 890-6.
31. Grover VP, Pavese N, Koh SB, et al,. Cerebral microglial activation with patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepatitis 2012; 19: e89-96.
32. Musselman DL, Lawson DH, Gumnick JF, et al,. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961-6.
33. Raison CL, Demetrashvili M, Capuron L, Miller AH,. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19: 105-23.
34. Schaefer M, Schmidt F, Folwaczny C, et al,. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-51.
35. Hauser P, Khosla J, Aurora H, et al,. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry 2002; 7: 942-7.
36. Leutscher PD, Lagging M, Buhl MR, et al,. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010; 52: 430-5.
37. Baraldi S, Hepgul N, Mondelli V, Pariante CM,. Symptomatic Treatment of Interferon Alpha Induced Depression in Hepatitis C: a Systematic Review. J Clin Psychopharmacol 2012; 32: 531-43.
38. Muir AJ, Shiffman ML, Zaman A, et al,. Phase 1b study of pegylated interferon lambda 1 with or without ribavarin in patients with chronic genotype 1 hepatitis C infection. Hepatology 2010; 52: 822-32.
39. Weinstein AA, Kallman Price J, Stepanova M, et al,. Depression in patients with nonalcoholic fatty liver disease and chronic viral hepatitis B and C. Psychosomatics 2011; 52: 127-32.
40. Foster GR, Goldin RD, Thomas HC,. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-12.
41. Marcellin P, Lau GK, Zeuzem S, et al,. Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alfa-2a. Liver Int 2008; 28: 474-82.
42. Cargiulo T,. Understand the health impact of alcohol dependence. Am J Health Syst Pharm 2007; 64 (5 Suppl 3): S5-11.
43. Ewusi-Mensah I, Saunders JB, Wodak AD, Murray RM, Williams R,. Psychiatric morbidity in patients with alcoholic liver disease. Br Med J 1983; 287: 1417-9.
44. Kelly M, Chick J, Gribble R, et al,. Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol Alcohol 2006; 41: 278-83.
45. Gedaly R, McHugh PP, Johnston TD, et al,. Predictors of relapse to alcohol and illicit drugs after liver transplantation for alcoholic liver disease. Transplantation 2008; 86: 1090-5.
46. Elwing JE, Lustman PJ, Hanlin HL, Clouse R,. Depression, anxiety and nonalcoholic steatohepatitis. Psychosom Med 2006; 68: 563-9.
47. Youssef NA, Abdelmalek MF, Binks M, et al,. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int 2013; 33: 1062-70.
48. Schramm C, Wahl I, Weiler-Normann C, et al,. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. J Hepatol 2014; 60: 618-24.
49. van Os E, van den Broek WW, Mulder PGH, et al,. Depression in patient with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2007; 46: 1099-103.
50. DiMartini A, Dew MA, Chaiffetz D, Fitzgerald MG, Devera ME, Fontes P,. Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long-term survival. Am J Transplant 2011; 11: 1287-95.
51. Miller LR, Paulson D, Eshelman A, et al,. Mental Health Affects the Quality of Life and Recovery After Liver Transplantation. Liver Transpl 2013; 19: 1272-8.
52. Zahn A, Seubert L, Jünger J, et al,. Factors influencing long-term quality of life and depression in German liver transplant recipients: a single-centre cross-sectional study. Ann Transplant 2013; 18: 327-35.
53. De Bona M, Ponton P, Ermani M, et al,. The impact of liver disease and medical complications on quality of life and psychosocial distress before and after liver transplantation. J Hepatol 2000; 33: 609-15.
54. Burra P, Germani G,. Long-Term Quality of Life for Transplant Recipients. Liver Transpl 2013; 19 (Suppl 2): S40-3.
55. Corruble E, Barry C, Varescon I, Falissard B, Castaing D, Samuel D,. Depressive symptoms predict long term mortality after liver transplantation. J Psychosom Res 2011; 71: 32-7.
56. Rogal SS, Dew MA, Fontes P, DiMartini AF,. Early treatment of depressive symptoms and long-term survival after liver transplantation. Am J Transplant 2013; 13: 928-35.
57. Errichiello L, Picozzi D, de Notaris EB,. Prevalence of psychiatric disorders and suicide ideation in liver transplanted patients: a cross-sectional study. Clin Res Hepatol Gastroenterol 2014; 38: 55-62.
58. Gorevski E, Succop P, Sachdeva J, et al,. Is there an association between immunosuppressant therapy medication adherence and depression, quality of life, and personality traits in the kidney and liver transplant population? Patient Prefer Adherence 2013; 7: 301-7.
59. Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM,. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 722-9.
60. 2B receptor in chronic liver disease. Nat Med 2011; 17: 1668-73.
61. Tian Y, Graf R, El-Badry AM, et al,. Activation of serotonin receptor-2B rescues small-for-size liver graft failure in mice. Hepatology 2011; 53: 253-62.
62. Diaz SL, Doly S, Narboux-Nême N, et al,. 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. Molecular Psychiatry 2012; 17: 154-63.
63. Burra P,. Sexual dysfunction after liver transplantation. Liver Transplant 2009; 15 (Suppl. 2): S50-6.
64. Verbeeck RK, Horsmans Y,. Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm World Sci 1998; 20: 183-92.
65. Crone CC, Gabriel GM,. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2004; 43: 361-94.
66. Verbeeck RK,. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147-61.
67. Lewis JH, Stine JG,. Review article: prescribing medications in patients with cirrhosis-a practical guide. Aliment Pharmacol Ther 2013; 37: 1132-56.
68. Franz CC, Egger S, Born C, Bravo AER, Krähenbühl S,. Potential drug-drug interactions and adverse drug reactions in patients with liver cirrhosis. Eur J Clin Pharmacol 2012; 68: 179-88.
69. Schenker S, Martin RR, Hoyumpa AM,. Antecdent liver disease and drug toxicity. J Hepatol 1999; 31: 1098-105.
70. Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labelling. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf. Accessed 23 June 2014.
71. European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function, 17th February 2005. Available at: www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003122.pdf. Accessed 23 June 2014.
72. Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jørgensen T, Sidhu J,. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 1998; 54: 237-42.
73. Areberg J, Christophersen JS, Poulsen MN, Larsen F, Molz K-H,. The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J 2006; 8: E14-9.
74. Schenker S, Bergstrom RF, Wolen RL, Lemberger L,. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988; 44: 353-9.
75. Bergstrom RF, Beasley CM Jr, Levy NB, Blumenfield M, Lemberger L,. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance and risk-benefit profile of fluoxetine. Int Clin Psychopharmacol 1993; 8: 261-6.
76. Dalhoff K, Almdal TP, Bjerrum K, Keiding S, Mengel H, Lund J,. Pharmacokinetics of paroxetine in patients with cirrhosis. Eur J Clin Pharmacol 1991; 41: 351-4.
77. Démolis J-L, Angebaud P, Grangé J-D, Coates P, Funck-Bretano C, Jaillon P,. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol 1996; 42: 394-7.
78. Cardona X, Avila A, Castellanos P,. Venlafaxine-associated hepatitis. Ann Intern Med 2000; 132: 417.
79. Hrdina PD, Lapierre YD, Koranyi EK,. Altered amitriptyline kinetics in a depressed patient with porto-caval anastomosis. Can J Psychiatry 1985; 30: 111-3.
80. Tran A, Laneury JP, Duchêne P, et al,. Pharmacokinetics of reboxetine in volunteers with hepatic impairment. Clin Drug Investig 2000; 19: 473-7.
81. Timmer CJ, Sitsen JM, Delbressine LP,. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461-74.
82. Andrade C, Sandarsh S, Chethan KB, Nagesh KS,. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565-75.
83. Skop BP, Brown TM,. Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors. Psychosomatics 1996; 37: 12-6.
84. Martin KA, Krahn LE, Balan V, Rosati MJ,. Selective serotonin reuptake inhibitors in the context of hepatitis C infection: re-examining the risks of bleeding. J Clin Psychiatry 2007; 68: 1024-6.
85. Weinrieb RM, Auriacombe M, Lynch KG, Chang K-M, Lewis JD,. A critical review of selective serotonin reuptake inhibitor-associated bleeding: balancing the risk of treating hepatitis C-infected patients. J Clin Psychiatry 2003; 64: 1502-10.
86. Delcò F, Tchambaz L, Schlienger R, Drewe J, Krähenbühl S,. Dose adjustment in patients with liver disease. Drug Saf 2005; 28: 529-45.
87. Lõpez-Torres E, Lucena MI, Seoane J, Verge C, Andrade RJ,. Hepatotoxicity related to citalopram. Am J Psychiatry 2004; 161: 923-4.
88. Carvajal Garcia-Pando A, Garcia del Pozo J, Sánchez SA, Velasco MA, Rueda de Castro AM, Lucena MI,. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 2002; 63: 135-7.
89. Vuppalanchi R, Hayashi PH, Chalasani N, et al,. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010; 32: 1174-83.
90. Park SH, Ishino R,. Liver injury associated with antidepressants. Curr Drug Saf 2013; 8: 207-23.
91. Gleason OC, Yates WR, Philipsen MA,. Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Companion J Clin Psychiatry 2005; 7: 225-30.
92. Kraus MR, Schäfer A, Schöttker K, et al,. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut 2008; 57: 531-6.
93. Kraus MR, Schäfer A, Faller H, Csef H, Scheurlen M,. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 1091-9.
94. Surman OS, Cosimi AB, DiMartini A,. Psychiatric care of patients undergoing organ transplantation. Transplantation 2009; 87: 1753-61.
95. Schlatter C, Egger SS, Tchambaz L, Krähenbühl S,. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. Drug Saf 2009; 32: 561-78.
96. Rosenblum LE, Korn RJ, Zimmerman H,. Hepatocellular jaundice as a complication of iproniazid therapy. Arch Intern Med 1960; 105: 583-93.
97. Stoeckel K, Pfefen JP, Mayersohn M, et al,. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand 1990; 360: 94-7.
98. Livingston MG, Livingston HM,. Monoamine oxidase inhibitors. An update on drug interactions. Drug Saf 1996; 14: 219-27.
99. Detry O, Delwaide J, De Roover A, et al,. Fulminant hepatic failure induced by venlafaxine and trazadone therapy: a case report. Transpl Proc 2009; 41: 3435-6.
100. Hui C, Yuen M, Wong W, Lam S, Lai C,. Mirtazapine-Induced Hepatotoxicity. J Clin Gastroenterol 2002; 35: 270-1.
101. Katz AJ, Dusetzina SB, Farley JF, et al. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. Pharmacotherapy 2012; 32: 234-43.
102. Horton RC, Bonser RS,. Interaction between cyclosporin and fluoxetine. BMJ 1995; 311: 422.
103. Vella JP, Sayegh MH,. Interactions between cyclosporine and newer antidepressant medications. Am J Kidney Dis 1998; 31: 320-3.
104. Liston HL, Markowitz JS, Hunt N, DeVane CL, Boulton DW, Ashcraft E,. Lack of citalopram effect on the pharmacokinetics of cyclosporine. Psychosomatics 2001; 42: 370-2.
105. Lill J, Bauer LA, Horn JR, Hansten PD,. Cyclosporine-drug interactions and the influence of patient age. Am J Health Syst Pharm 2000; 57: 1579-84.
106. Markowitz JS, Gill HS, Hunt NM, Monroe RR Jr, DeVane CL,. Lack of antidepressant-cyclosporine pharmacokinetic interactions. J Clin Psychopharmacol 1998; 18: 91-3.
107. Zaydfudim V, Feurer ID, Landman MP, Moore DE, Kelly Wright J, Wright Pinson C,. Reduction in corticosteroids is associated with better health-related quality of life after liver transplantation. J Am Coll Surg 2012; 214: 164-73.